| AI-Powered Precision Medicine in the Future of Healthcare |
|
| | Tempus AI (NASDAQ: TEM) is leading a transformation in healthcare by using artificial intelligence to deliver personalized medical solutions. | With an $11 billion market cap and partnerships with industry leaders like AstraZeneca, Tempus leverages 300 petabytes of genomic data and tools like the Olivia AI assistant to dominate the $50 billion AI healthcare market. | Its work in accelerating oncology research and matching patients to clinical trials positions it as a top pick for tech investors looking to capitalize on precision medicine's growth. |
|
| | Watchlist (Sponsored) | | | Thanks to nonstop market chaos, most investors are stuck reacting — not preparing. | But with one simple step, you can flip the script and get ahead of the next potential breakout. | Our team at Krypton Street is about to release a free stock alert on a little-known company we've carefully researched for short-term upside. | You'll get the name, the ticker, and the full scoop — delivered right to you. | Remember Alarum Technologies (ALAR)? It jumped from just $2 to over $45 — a 2,100% gain that left most investors in the dust. | These setups don't happen every day, but when they do… they move fast. | Don't wait for the headlines. Be early. | Click Here to Discover the Market's Next Hidden Gem | (By clicking this link, you agree to receive emails from Kryptonstreet. You can opt out at any time. - Privacy Policy) |
|
| | Operational Overview and Recent Earnings | Tempus delivers three main services: genomic testing for oncology and hereditary conditions, data licensing for pharma and biotech, and AI applications to optimize patient care and research. | Its Genomics segment, which generates 76% of revenue, focuses on cancer and hereditary testing, while Data Services (24%) licenses insights from 40 million patient records. AI tools like Olivia and Tempus One enhance trial matching and patient engagement. | In Q1 2025, Tempus reported $256 million in revenue, up 75% year-over-year. The Ambry Genetics acquisition drove Genomics revenue to $194 million, an 89% increase, with oncology tests rising 31% to 75,000 and hereditary tests up 23% to 78,000. | Data Services grew 43% to $62 million, boasting 74% gross margins. The adjusted EBITDA loss shrank to $16 million from $44 million, beating estimates by $7 million, though cash burn rose to $108 million due to growth investments. | In 2024, revenue grew 30% to $1 billion, but 2025's surge reflects Tempus's ability to scale. Its network reaches 65% of U.S. academic medical centers and 50% of oncologists, providing unmatched access. | Gross profit jumped 99.8% in Q1, and improving margins show operational discipline, even as the company invests heavily in expansion. | Action Item: Buy Tempus shares to ride its growth trajectory. Watch Q2 2025 revenue and cash burn, as sustained execution is key to profitability. Monitor 2025 AI adoption rates and regulatory shifts for healthcare demand signals. |
|
|
| | Small Cap (Sponsored) | | | With volatility gripping the markets in 2025, speed and timing are everything.
That's why smart traders are turning to Market Crux — a research team that delivers handpicked alerts designed to uncover breakout potential before the mainstream catches on. | It only takes 3 steps to get started: | | Just look at GeneDx Holdings (WGS) — it quietly surged from $1.16 to $31 in under 12 months. That's over 2,600%… and it never made major headlines. | Let Market Crux be your unfair advantage in spotting the next one. | Click Here to Get the Next Alerts with Big Upside Potential | (By clicking this link, you agree to receive emails from Market Crux. You can opt out at any time. - Privacy Policy) |
|
| | Competitive Edge in Precision Medicine | Tempus stands out by combining scale, technology, and partnerships. Its 40 million patient records and 300 petabytes of data surpass competitors like Guardant Health, enabling AI tools that match patients to clinical trials 30% faster than traditional methods. | A $150 million R&D budget, 12% of revenue, supports innovations like the xT CDx test, priced at $4,500, which has raised average selling prices to $1,590. | Acquisitions are strengthening its position. The $600 million Ambry deal, closed in February 2025, expands hereditary and cardiovascular testing, while the March 2025 acquisition of Deep6 AI improves trial recruitment across 750 provider sites. | These moves have boosted data licensing retention to 140%. Partnerships with AstraZeneca, Pfizer, and GSK, including a $200 million oncology deal, solidify Tempus's role as a trusted pharma partner. | Unlike Flatiron Health, which focuses solely on data analytics, Tempus offers a comprehensive platform covering testing, AI, and trial matching. | With 4,000 institutional ties and scalable AI, Tempus leads in oncology, where speed and accuracy are critical. Its Olivia app, which helps patients navigate health data, is gaining traction, strengthening ties with providers and boosting engagement. | |
|
| Big Moves (Sponsored) | | | The secret to finding big moves that could end up like the ones below is knowing where to look: | Triller Group Inc (ILLR): From $.66 to $8.86 (+1,242%) Quantum Computing Inc (QUBT): From $.35 to $4.69 (+1,240%) Eco Wave Power (WAVE): From $1.01 to $12.39 (+1,126%)
| The choice is yours: You can do nothing, and you'll end up on the sidelines for the next +1,200% move. Or you can take action… |
Not long from now, Market Pulse Today will reveal its first alert of the quarter—a company with serious breakout potential.
| The best part? | It's 100% free. | You can make it happen or wonder "What happened?" | [Click Here to Get the Alert First]
(By clicking this link, you will automatically be subscribed to the Market Pulse Today. - Privacy Policy) |
|
| | Bear Case | Investing in Tempus comes with hurdles: | Guardant Health's liquid biopsy tests, such as Guardant360, are competitive and could erode Tempus's market share. Regulatory delays, like MolDx's pending approval for minimal residual disease (MRD) tests, may hinder new launches. Quarterly cash burn of $108 million, with $219 million in cash reserves, raises dilution risks if growth slows. Economic slowdowns could tighten hospital budgets. Integration challenges from Ambry and Deep6 could disrupt operations. Data privacy concerns also pose a litigation risk, which could shake investor confidence.
|
|
| | Tempus AI's Precision Play Heals Tech Portfolios | Tempus is poised for a breakout year. Management projects $1.25 billion in 2025 revenue, an 80% increase from 2024's 30% growth, per Q1 filings. Genomics will account for 60% of this growth, with hereditary testing expanding post-Ambry. | Data Services, with $940 million in remaining contract value, is expected to grow 40% annually, driven by pharma deals. Adjusted EBITDA is forecast to turn positive at $5 million in 2025, a $110 million improvement, signaling a path to profitability. | A 25% organic growth rate, combined with plans for xH whole-genome sequencing by 2026, keeps Tempus ahead of competitors. | Regulatory risks, such as MolDx delays, could create short-term challenges, but its data scale and institutional reach provide stability. | New initiatives, like 1,000 AI agents integrated into hospital EHR systems and a Q2 2025 immunotherapy assay, position Tempus to capture more of the oncology market and ultimately combine to make this a standout MedTech stock for the long run. |
|
| | That's our coverage for today; thanks for reading! Reply to this email with feedback or any tech stocks you want me to check out. | Best Regards,
—Noah Zelvis
Tech Stock Insider |
|
